Literature DB >> 8383183

Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin.

T Ragot1, S Finerty, P E Watkins, M Perricaudet, A J Morgan.   

Abstract

A replication-defective recombinant adenovirus (Ad) expressing the full length Epstein-Barr virus (EBV) major envelope glycoprotein gp340/220 was tested for its ability to protect against EBV-induced lymphoma in the cottontop tamarin. Antibody responses against Ad capsid proteins and EBV gp340/220 were observed but these antibodies did not neutralize EBV in vitro. However, all immunized animals were protected against challenge following three intramuscular doses of the recombinant Ad. These data indicate that the recombinant Ad is potentially a useful vector for vaccination.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8383183     DOI： 10.1099/0022-1317-74-3-501

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  21 in total

Review 1.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 2.  Non-replicating expression vectors: applications in vaccine development and gene therapy.

Authors:  K J Limbach; E Paoletti
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

3.  High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.

Authors:  Anna E Coghill; Wei Bu; Hanh Nguyen; Wan-Lun Hsu; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Chien-Jen Chen; Allan Hildesheim; Jeffrey I Cohen
Journal:  Clin Cancer Res       Date:  2016-02-26       Impact factor: 12.531

4.  Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene.

Authors:  N Deconinck; T Ragot; G Maréchal; M Perricaudet; J M Gillis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

Review 5.  Prospects of a novel vaccination strategy for human gamma-herpesviruses.

Authors:  Ting-Ting Wu; Marcia A Blackman; Ren Sun
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

6.  Latent Epstein-Barr virus infection in cottontop tamarins. A possible model for Epstein-Barr virus infection in humans.

Authors:  G Niedobitek; A Agathanggelou; S Finerty; R Tierney; P Watkins; E L Jones; A Morgan; L S Young; N Rooney
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

7.  Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.

Authors:  P W Chen; M Wang; V Bronte; Y Zhai; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

8.  Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.

Authors:  Junji Sashihara; Peter D Burbelo; Barbara Savoldo; Theodore C Pierson; Jeffrey I Cohen
Journal:  Virology       Date:  2009-07-07       Impact factor: 3.616

9.  A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.

Authors:  Xinle Cui; Zhouhong Cao; Goutam Sen; Gouri Chattopadhyay; Deborah H Fuller; James T Fuller; Dustin M Snapper; Andrew L Snow; James J Mond; Clifford M Snapper
Journal:  Vaccine       Date:  2013-05-09       Impact factor: 3.641

10.  Evaluation of Total and IgA-Specific Antibody Targeting Epstein-Barr Virus Glycoprotein 350 and Nasopharyngeal Carcinoma Risk.

Authors:  Anna E Coghill; Wei Bu; Wan-Lun Hsu; Hanh Nguyen; Kelly J Yu; Yin-Chu Chien; Chien-Jen Chen; Jeffrey I Cohen; Allan Hildesheim
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.